<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Johnson & Johnson (JNJ) - TickerHack Deep Research</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
            background-color: #F5F5F4; /* stone-100 */
            color: #374151; /* gray-700 */
        }
        .chart-container {
            position: relative;
            width: 100%;
            max-width: 600px;
            margin-left: auto;
            margin-right: auto;
            height: 300px;
            max-height: 350px;
        }
        @media (min-width: 768px) { /* md */
            .chart-container {
                height: 350px;
                max-height: 400px;
            }
        }
        .section-card {
            background-color: #FFFFFF;
            border-radius: 0.75rem; /* rounded-xl */
            box-shadow: 0 10px 15px -3px rgba(0, 0, 0, 0.07), 0 4px 6px -2px rgba(0, 0, 0, 0.04); /* Softer shadow */
            padding: 1.5rem; /* p-6 */
            margin-bottom: 2rem; /* mb-8 */
        }
        .main-title {
            font-size: 2.25rem; /* text-4xl */
            font-weight: 700; /* font-bold */
            color: #1F2937; /* gray-800 */
            margin-bottom: 1rem;
            text-align: center;
        }
        .section-title {
            font-size: 1.875rem; /* text-3xl */
            font-weight: 600; /* font-semibold */
            color: #BE123C; /* rose-700 */
            margin-bottom: 1.5rem; /* mb-6 */
            padding-bottom: 0.5rem; /* pb-2 */
            border-bottom: 2px solid #E7E5E4; /* stone-200 */
        }
        .subsection-title {
            font-size: 1.5rem; /* text-2xl */
            font-weight: 600; /* font-semibold */
            color: #E11D48; /* rose-600 */
            margin-top: 1.5rem; /* mt-6 */
            margin-bottom: 1rem; /* mb-4 */
        }
        .content-text {
            line-height: 1.75;
            color: #4B5563; /* gray-600 */
            font-size: 0.95rem;
        }
        .highlight {
            color: #0369A1; /* cyan-700 */
            font-weight: 600;
        }
        .nav-link {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem; /* rounded-md */
            font-weight: 500;
            color: #374151; /* gray-700 */
            transition: background-color 0.2s ease-in-out, color 0.2s ease-in-out;
            white-space: nowrap;
        }
        .nav-link:hover, .nav-link.active {
            background-color: #BE123C; /* rose-700 */
            color: #FFFFFF;
        }
        .kpi-card {
            background-color: #F9FAFB; /* gray-50 */
            border: 1px solid #E7E5E4; /* stone-200 */
            border-radius: 0.5rem; /* rounded-lg */
            padding: 1rem;
            text-align: center;
        }
        .kpi-label {
            font-size: 0.875rem; /* text-sm */
            color: #6B7280; /* gray-500 */
            margin-bottom: 0.25rem;
        }
        .kpi-value {
            font-size: 1.75rem; /* text-2xl or 3xl */
            font-weight: 600;
            color: #1F2937; /* gray-800 */
        }
    </style>
</head>
<body class="min-h-screen">

    <header class="sticky top-0 z-50 bg-white/95 backdrop-blur-md shadow-md">
        <nav class="container mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex items-center justify-between h-16">
                <div class="flex-shrink-0">
                    <h1 class="text-xl font-bold" style="color: #BE123C;">Johnson & Johnson (JNJ) Analysis</h1>
                </div>
                <div class="hidden md:block">
                    <div class="ml-10 flex items-baseline space-x-1 lg:space-x-2">
                        <a href="#overview" class="nav-link">Overview</a>
                        <a href="#segments" class="nav-link">Business Segments</a>
                        <a href="#financials" class="nav-link">Financials</a>
                        <a href="#competition" class="nav-link">Competitive Moat</a>
                        <a href="#outlook" class="nav-link">Outlook</a>
                    </div>
                </div>
                <div class="md:hidden">
                    <button id="mobile-menu-button" type="button" class="inline-flex items-center justify-center p-2 rounded-md text-gray-500 hover:text-gray-700 hover:bg-gray-100 focus:outline-none focus:ring-2 focus:ring-inset focus:ring-rose-500" aria-controls="mobile-menu" aria-expanded="false">
                        <span class="sr-only">Open main menu</span>
                        <svg class="block h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16" /></svg>
                        <svg class="hidden h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12" /></svg>
                    </button>
                </div>
            </div>
            <div class="md:hidden hidden" id="mobile-menu">
                <div class="px-2 pt-2 pb-3 space-y-1 sm:px-3">
                    <a href="#overview" class="nav-link block text-base">Overview</a>
                    <a href="#segments" class="nav-link block text-base">Business Segments</a>
                    <a href="#financials" class="nav-link block text-base">Financials</a>
                    <a href="#competition" class="nav-link block text-base">Competitive Moat</a>
                    <a href="#outlook" class="nav-link block text-base">Outlook</a>
                </div>
            </div>
        </nav>
    </header>

    <main class="container mx-auto p-4 md:p-6 lg:p-8 mt-4">

        <section id="overview" class="section-card scroll-mt-20">
            <h2 class="section-title">The New J&J: A Sharpened Focus on Innovation & Technology</h2>
            <p class="content-text mb-6">Johnson & Johnson has fundamentally reshaped its business to focus on its two most innovative, highest-growth segments: <span class="highlight">Innovative Medicine</span> and <span class="highlight">MedTech</span>. Following the successful spin-off of its consumer health division into Kenvue (KVUE), the new J&J is a more streamlined and agile healthcare powerhouse. The company is now dedicated to tackling the world's most complex diseases and medical challenges, leveraging its immense R&D capabilities and global scale to deliver breakthrough therapies and life-saving medical technologies. This analysis explores the strategy, financials, and outlook for this more focused, modern Johnson & Johnson.</p>
            
            <div class="grid md:grid-cols-2 gap-6 items-start">
                <div>
                    <h3 class="subsection-title !mt-0">Core Business Strategy</h3>
                    <p class="content-text mb-4">J&J's post-spinoff strategy is clear and focused:</p>
                    <ul class="list-disc list-inside content-text space-y-1 pl-4">
                        <li><strong class="font-semibold text-gray-700">Lead with Science & Technology:</strong> Directing its massive R&D budget towards developing novel drugs and next-generation medical devices.</li>
                        <li><strong class="font-semibold text-gray-700">Win in High-Growth Markets:</strong> Aggressively pursuing leadership in areas like oncology and immunology, and strategically acquiring companies like Abiomed and Shockwave to dominate the cardiovascular device market.</li>
                        <li><strong class="font-semibold text-gray-700">Navigate Patent Expirations:</strong> Advancing a robust pipeline of new products to offset the upcoming loss of exclusivity for blockbuster drugs like Stelara.</li>
                        <li><strong class="font-semibold text-gray-700">Deliver Shareholder Value:</strong> Maintaining its "Dividend King" status with consistent dividend growth, supplemented by strategic share buybacks and investments.</li>
                    </ul>
                </div>
                 <div class="grid grid-cols-2 gap-4">
                    <div class="kpi-card bg-rose-50 border-rose-200">
                        <p class="kpi-label">2024 Sales</p>
                        <p class="kpi-value text-rose-600">$88.6B</p>
                    </div>
                     <div class="kpi-card bg-rose-50 border-rose-200">
                        <p class="kpi-label">Annual R&D Investment</p>
                        <p class="kpi-value text-rose-600">$15B+</p>
                    </div>
                </div>
            </div>
        </section>

        <section id="segments" class="section-card scroll-mt-20">
            <h2 class="section-title">How J&J Makes Money: Two Powerful Engines</h2>
            <p class="content-text mb-6">Johnson & Johnson's revenue is now driven by two complementary, high-margin segments. Innovative Medicine provides the high-profitability engine through patented drugs, while MedTech offers durable growth through essential medical technologies. This combination creates a resilient and powerful business model poised to address the full continuum of care.</p>

            <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                <div>
                    <h3 class="subsection-title">Segment Performance (FY 2024 Revenue)</h3>
                    <p class="content-text mb-2">The <span class="highlight">Innovative Medicine</span> segment is the larger of the two, representing over 60% of total sales. It is driven by a portfolio of blockbuster drugs in immunology and oncology. The <span class="highlight">MedTech</span> segment is a significant contributor with strong positions in surgery, orthopaedics, vision, and a rapidly growing presence in interventional cardiovascular solutions.</p>
                     <ul class="list-disc list-inside content-text space-y-1 pl-4 mt-4">
                        <li><strong>Innovative Medicine:</strong> Develops and sells patented drugs for cancer, autoimmune diseases, and other serious conditions.</li>
                        <li><strong>MedTech:</strong> Sells medical devices, equipment, and technology used in surgical and clinical settings, with a growing focus on high-tech cardiovascular solutions.</li>
                    </ul>
                </div>
                <div class="chart-container h-72 md:h-80">
                    <canvas id="segmentRevenueBreakdownChart"></canvas>
                </div>
            </div>
        </section>

        <section id="financials" class="section-card scroll-mt-20">
            <h2 class="section-title">Financial Deep Dive</h2>
            <p class="content-text mb-6">J&J's financial strength is a cornerstone of its business. The company consistently generates robust sales, strong earnings, and massive free cash flow, providing the resources to fund its strategic priorities. Financials below reflect the new, two-segment structure. Explore key financial trends using the dropdowns below to visualize both long-term annual performance and recent quarterly results.</p>
            
            <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title">Fiscal Year Trends (2022-2024)</h3>
                    <div class="mb-4">
                        <label for="yearlyMetricSelect" class="block text-sm font-medium text-gray-700 mb-1">Select Annual Metric:</label>
                        <select id="yearlyMetricSelect" class="block w-full p-2 border border-stone-300 rounded-md shadow-sm focus:ring-rose-500 focus:border-rose-500">
                            <option value="totalRevenue" selected>Total Revenue ($B)</option>
                            <option value="operatingIncome">Adjusted Operating Income ($B)</option>
                            <option value="netIncome">Adjusted Net Income ($B)</option>
                            <option value="operatingCashFlow">Operating Cash Flow ($B)</option>
                        </select>
                    </div>
                    <div id="yearlyFinancialChartContainer" class="chart-container h-80 max-w-full">
                        <canvas id="yearlyFinancialChart"></canvas>
                    </div>
                </div>

                <div>
                    <h3 class="subsection-title">Quarterly Trends (Recent 5 Qtrs)</h3>
                     <div class="mb-4">
                        <label for="quarterlyMetricSelect" class="block text-sm font-medium text-gray-700 mb-1">Select Quarterly Metric:</label>
                        <select id="quarterlyMetricSelect" class="block w-full p-2 border border-stone-300 rounded-md shadow-sm focus:ring-rose-500 focus:border-rose-500">
                            <option value="totalRevenue" selected>Total Revenue ($B)</option>
                            <option value="innovativeMedicine">Innovative Medicine Sales ($B)</option>
                            <option value="medTech">MedTech Sales ($B)</option>
                        </select>
                    </div>
                    <div id="quarterlyFinancialChartContainer" class="chart-container h-80 max-w-full">
                        <canvas id="quarterlyFinancialChart"></canvas>
                    </div>
                </div>
            </div>
             <p class="content-text text-sm mt-6 text-center">Financial trends demonstrate the stable growth of the combined enterprise, with MedTech providing consistent results and Innovative Medicine driving overall growth, albeit subject to product cycles.</p>
        </section>

        <section id="competition" class="section-card scroll-mt-20">
            <h2 class="section-title">Competitive Moat: A Fortress of Science and Scale</h2>
            <p class="content-text mb-6">Johnson & Johnson's competitive advantages are deep and multifaceted, creating a formidable barrier to entry that protects its long-term profitability and market leadership.</p>
            
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title !mt-0">Key Moats</h3>
                    <ul class="list-none space-y-3">
                        <li class="flex items-start">
                            <span class="text-rose-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Intellectual Property & Patents:</strong> A vast portfolio of drug and device patents provides market exclusivity, enabling high-margin sales and funding the next wave of innovation.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-rose-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Economies of Scale:</strong> J&J's sheer size gives it tremendous cost advantages in manufacturing, global distribution, and marketing. Its ability to spend over $15 billion annually on R&D is a moat in itself.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-rose-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Entrenched Relationships:</strong> Decades of building trust with surgeons, doctors, and hospitals create high switching costs. Clinicians are often trained on J&J devices and are familiar with their drugs, making them reluctant to switch.</span>
                        </li>
                         <li class="flex items-start">
                            <span class="text-rose-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Brand & Reputation:</strong> The J&J name is a powerful asset, synonymous with quality, safety, and scientific rigor within the global healthcare community.</span>
                        </li>
                    </ul>
                </div>
                <div>
                    <h3 class="subsection-title !mt-0">Primary Competitors</h3>
                     <ul class="list-none space-y-3">
                        <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">●</span>
                            <span class="content-text"><strong class="text-gray-700">Innovative Medicine:</strong> AbbVie, Merck, Bristol Myers Squibb, Roche, Pfizer, Novartis.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">●</span>
                            <span class="content-text"><strong class="text-gray-700">MedTech:</strong> Medtronic, Stryker, Abbott, Edwards Lifesciences, Intuitive Surgical, Siemens Healthineers.</span>
                        </li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="outlook" class="section-card scroll-mt-20">
            <h2 class="section-title">Strategic Outlook: Risks & Rewards</h2>
            <p class="content-text mb-6">The future for the new Johnson & Johnson is a compelling story of opportunity balanced by significant, well-defined challenges. Success will depend on executing its innovation strategy while navigating major near-term headwinds.</p>
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title !mt-0 text-teal-600">Rewards & Opportunities 🚀</h3>
                    <ul class="list-disc list-inside content-text space-y-2 pl-4">
                        <li><strong>Robust R&D Pipeline:</strong> Potential to launch over 20 new therapies by 2030, many with blockbuster potential, to fuel long-term growth.</li>
                        <li><strong>MedTech Leadership:</strong> Transformative acquisitions are creating a dominant force in the high-growth cardiovascular device market.</li>
                        <li><strong>Financial Firepower:</strong> Massive cash flow generation provides flexibility for further strategic acquisitions, R&D investment, and shareholder returns.</li>
                        <li><strong>Dividend King Status:</strong> A rock-solid, growing dividend provides a reliable return floor for investors, underscoring financial stability.</li>
                    </ul>
                </div>
                <div>
                    <h3 class="subsection-title !mt-0 text-orange-600">Risks & Challenges 📉</h3>
                    <ul class="list-disc list-inside content-text space-y-2 pl-4">
                        <li><strong>The Stelara Patent Cliff:</strong> The imminent loss of exclusivity in the U.S. for this ~$10B drug is the single largest and most certain risk to near-term revenue.</li>
                        <li><strong>Talc Litigation Overhang:</strong> The ongoing, multi-billion dollar talc-related lawsuits create significant financial and reputational uncertainty.</li>
                        <li><strong>Pipeline & Integration Risk:</strong> Drug development is inherently risky, and there is no guarantee of clinical trial success. Integrating large acquisitions also carries significant execution risk.</li>
                        <li><strong>Regulatory Pressure:</strong> Global governments and payors continue to pressure drug pricing, which could impact future profitability.</li>
                    </ul>
                </div>
            </div>
        </section>

        <footer class="bg-stone-800 text-stone-300 py-8 text-center mt-12">
            <p class="text-sm">&copy; <span id="currentYearFooter"></span> TickerHack Deep Research. For informational purposes only.</p>
            <p class="text-xs mt-1">Data synthesized from Johnson & Johnson public filings and credible financial news sources as of June 2025.</p>
        </footer>

    <script>
        document.getElementById('currentYearFooter').textContent = new Date().getFullYear();

        // Mobile menu toggle
        const mobileMenuBtn = document.getElementById('mobile-menu-button');
        const mobileMenuEl = document.getElementById('mobile-menu');
        mobileMenuBtn.addEventListener('click', () => {
            mobileMenuEl.classList.toggle('hidden');
            mobileMenuBtn.querySelectorAll('svg').forEach(svg => svg.classList.toggle('hidden'));
        });
        
        const navLinks = document.querySelectorAll('header nav a[href^="#"]');
        navLinks.forEach(link => {
            link.addEventListener('click', (e) => {
                if (!mobileMenuEl.classList.contains('hidden')) {
                    mobileMenuBtn.click();
                }
                navLinks.forEach(l => l.classList.remove('active'));
                e.currentTarget.classList.add('active');
            });
        });

        // Chart.js Global Config
        Chart.defaults.font.family = 'Inter, sans-serif';
        Chart.defaults.color = '#4B5563';

        const CHART_COLORS = {
            rose: '#E11D48',
            sky: '#0EA5E9',
            orange: '#F97316',
            amber: '#F59E0B',
            gray: '#6B7280',
            darkRose: '#BE123C',
        };

        // Segment Revenue Breakdown Chart (Pie) - FY2024 Data
        const segmentRevenueCtx = document.getElementById('segmentRevenueBreakdownChart').getContext('2d');
        new Chart(segmentRevenueCtx, {
            type: 'pie',
            data: {
                labels: ['Innovative Medicine', 'MedTech'],
                datasets: [{
                    data: [55.2, 33.4], // FY24 Data in $B (approx)
                    backgroundColor: [CHART_COLORS.darkRose, CHART_COLORS.sky],
                    hoverOffset: 4
                }]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                plugins: { legend: { position: 'bottom' }, title: { display: true, text: 'Segment Revenue Contribution (FY2024, $B)' } }
            }
        });

        // --- FINANCIAL CHARTS LOGIC ---

        // Yearly Data Store (Adjusted for 2-segment view)
        const yearlyDataStore = {
            labels: ['FY22', 'FY23', 'FY24'],
            totalRevenue: { data: [84.1, 85.2, 88.6], label: 'Total Revenue ($B)', color: CHART_COLORS.darkRose },
            operatingIncome: { data: [28.2, 28.5, 30.1], label: 'Adjusted Operating Income ($B)', color: CHART_COLORS.sky },
            netIncome: { data: [23.7, 24.0, 25.4], label: 'Adjusted Net Income ($B)', color: CHART_COLORS.rose },
            operatingCashFlow: { data: [21.3, 22.8, 23.5], label: 'Operating Cash Flow ($B)', color: CHART_COLORS.orange },
        };

        // Quarterly Data Store
        const quarterlyDataStore = {
             labels: ['Q1 24', 'Q2 24', 'Q3 24', 'Q4 24', 'Q1 25'],
            totalRevenue: { data: [21.0, 22.3, 22.2, 23.1, 22.5], label: 'Total Revenue ($B)', color: CHART_COLORS.darkRose },
            innovativeMedicine: { data: [13.4, 13.7, 13.9, 14.2, 14.0], label: 'Innovative Medicine Sales ($B)', color: CHART_COLORS.rose },
            medTech: { data: [7.6, 8.6, 8.3, 8.9, 8.5], label: 'MedTech Sales ($B)', color: CHART_COLORS.sky },
        };

        let yearlyChart = null;
        let quarterlyChart = null;
        const yearlySelect = document.getElementById('yearlyMetricSelect');
        const quarterlySelect = document.getElementById('quarterlyMetricSelect');
        const yearlyCanvas = document.getElementById('yearlyFinancialChart').getContext('2d');
        const quarterlyCanvas = document.getElementById('quarterlyFinancialChart').getContext('2d');

        function createChart(canvas, existingChart, dataStore, metricKey) {
            if (existingChart) {
                existingChart.destroy();
            }
            const metricDetails = dataStore[metricKey];
            return new Chart(canvas, {
                type: 'bar',
                data: {
                    labels: dataStore.labels,
                    datasets: [{
                        label: metricDetails.label,
                        data: metricDetails.data,
                        backgroundColor: metricDetails.color + 'BF',
                        borderColor: metricDetails.color,
                        borderWidth: 1,
                         tension: 0.1
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    scales: { y: { beginAtZero: false, title: { display: true, text: metricDetails.label.split('(')[1].replace(')','')} } },
                    plugins: { legend: { display: false } }
                }
            });
        }
        
        yearlySelect.addEventListener('change', (event) => {
            yearlyChart = createChart(yearlyCanvas, yearlyChart, yearlyDataStore, event.target.value);
        });

        quarterlySelect.addEventListener('change', (event) => {
            quarterlyChart = createChart(quarterlyCanvas, quarterlyChart, quarterlyDataStore, event.target.value);
        });

        // Initial chart renders
        yearlyChart = createChart(yearlyCanvas, yearlyChart, yearlyDataStore, 'totalRevenue');
        quarterlyChart = createChart(quarterlyCanvas, quarterlyChart, quarterlyDataStore, 'totalRevenue');

    </script>
</body>
</html>

